Viral hepatitis

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024

Retrieved on: 
水曜日, 5月 22, 2024
Doctor of Philosophy, EASL, Treatment, Genital herpes, Viral, Poster, Safety, SAN, Assembly, Gilead Sciences, HSV, HDV, Cirrhosis, Hepatitis D, Viral hepatitis, Injection, Abstract, Therapy, Biotechnology, Standard of care, Vaccine

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the company will present data from its herpes simplex virus (HSV) and hepatitis D virus (HDV) pipeline programs at upcoming medical congresses. Assembly Bio’s abstracts for ABI-5366 and ABI-1179 have been accepted for one oral and two poster presentations at the International Herpesvirus Workshop, taking place in Portland, Ore., July 13-17, 2024. An abstract for ABI-6250 has been accepted for poster presentation at the European Association for the Study of the Liver (EASL) Congress™ 2024 taking place in Milan, Italy, June 5-8, 2024.

Key Points: 
  • Assembly Bio’s abstracts for ABI-5366 and ABI-1179 have been accepted for one oral and two poster presentations at the International Herpesvirus Workshop, taking place in Portland, Ore., July 13-17, 2024.
  • An abstract for ABI-6250 has been accepted for poster presentation at the European Association for the Study of the Liver (EASL) Congress™ 2024 taking place in Milan, Italy, June 5-8, 2024.
  • At the International Herpesvirus Workshop, Assembly Bio will present data describing the preclinical profile of ABI-5366, a long-acting helicase-primase inhibitor candidate in development for the treatment of recurrent genital herpes.
  • “We’re excited to present data from both of these potent, long-acting HSV helicase-primase inhibitors at the International Herpesvirus Workshop,” said William Delaney, PhD, chief scientific officer of Assembly Bio.

Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024

Retrieved on: 
水曜日, 5月 22, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Hospitals, Clinical Trials, Hepatitis C, Risk, Medicaid, FDA, Senior, PBC, Congress, HDV, Itch, HCV, Woman, Cirrhosis, Abstract (summary), Bulevirtide, European Economic Area, Hepatitis, Liver disease, Ascending cholangitis, HBV, MD, Civil service commission, European Commission, Primary biliary cholangitis, Ursodeoxycholic acid, Gross metropolitan product, Food, Education, Disease, Safety, Gilead Sciences, ULN, Incidence, Policy, Alkaline phosphatase, Viral hepatitis, WHO, Liver cancer, Liver failure, Patient, EASL, Diagnosis, Abstract, UDCA, Fatigue, Quality of life, ALP, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, June 5-8, 2024 in Milan, Italy.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, June 5-8, 2024 in Milan, Italy.
  • “These data underline Gilead’s commitment to drive life-changing science and create healthier futures for people living with liver disease.
  • “The breadth of our data being presented across viral and inflammatory liver diseases, speaks to our commitment to driving positive change at every step of a person’s journey.
  • Further highlighting Gilead as a leader in HDV research, a sub-analysis of the MYR204 study (OS-122) evaluating intrahepatic virological outcomes 24 Weeks off-treatment will be presented.

Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024

Retrieved on: 
水曜日, 5月 22, 2024
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, APHP, Hepatology, Clinical research, Viral hepatitis, ALT, AASLD, University, Poster, Safety, Congress, Tariq, Interim, Abstract, Cirrhosis, Liver, Vaccine

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting new data from the Company’s chronic hepatitis delta and chronic hepatitis B programs have been accepted for presentation at the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2024, taking place in Milan, Italy from June 5-8.

Key Points: 
  • Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting new data from the Company’s chronic hepatitis delta and chronic hepatitis B programs have been accepted for presentation at the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2024, taking place in Milan, Italy from June 5-8.
  • This includes an oral presentation on June 8, which was originally accepted as a late-breaker poster , that will highlight the Company’s latest Phase 2 SOLSTICE trial data.
  • The oral presentation will include data on participants who have reached 12 and 24 weeks of chronic suppressive treatment.
  • “Vir remains steadfast in its mission to develop a transformative chronic suppressive therapy for the estimated 12 million or more people living with chronic hepatitis delta.

World Hepatitis Summit 2024 Convenes in Lisbon

Retrieved on: 
木曜日, 4月 4, 2024
Vaccination, Summit, WHO, Diagnosis, WHA, Viral hepatitis, ECDC, Friends, Policy, WHS, Family, Treatment, Private sector, Hepatitis B, COVID-19, Hepatitis, Vaccine

The World Hepatitis Summit (WHS) 2024 Will Bring Together Global Experts to Discuss the Latest Advances in Hepatitis Prevention, Diagnosis and Treatment

Key Points: 
  • The World Hepatitis Summit (WHS) 2024 Will Bring Together Global Experts to Discuss the Latest Advances in Hepatitis Prevention, Diagnosis and Treatment
    LONDON, Apr 4, 2024 - (ACN Newswire) - The World Hepatitis Summit (WHS) 2024 convenes in Lisbon from 9 - 11 April and will bring together global experts to discuss the latest advances in hepatitis prevention, diagnosis and treatment.
  • At the Summit, the World Hepatitis Alliance (WHA) and The European Centre for Disease Prevention and Control (ECDC) will present findings from a first-of-its-kind report examining levels of stigma and discrimination surrounding people living with hepatitis in Europe.
  • The report finds that half (50%) of those living with hepatitis B and C struggle to tell people about their hepatitis.
  • On the opening day of the Summit, WHO will release its 2024 Global Hepatitis Report.

Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant

Retrieved on: 
月曜日, 3月 18, 2024
Infectious Diseases, Hospitals, Public Policy, Government, Philanthropy, Managed Care, Health, State, Local, General Health, Foundation, Pregnancy, Liver failure, HBI, Organization, University, Hepatitis B, Disease, CDA, Cirrhosis, Patient, Public, HBV, Woman, Viral hepatitis, Medicaid, Liver cancer, Refugee, HCV, Pharmaceutical industry

“CDA Foundation is very proud to have been selected to distribute these grants,” commented Homie Razavi, the Managing Director of CDA Foundation.

Key Points: 
  • “CDA Foundation is very proud to have been selected to distribute these grants,” commented Homie Razavi, the Managing Director of CDA Foundation.
  • “Loss of diagnosed but untreated patients is a major barrier for countries trying to achieve the viral hepatitis elimination targets.
  • The submission window for the second round of proposals opened in February 2024 for programs with a duration of no more than 18 months.
  • For more information, please visit https://cdafound.org/relink or contact CDA Foundation at [email protected] .

Government of Canada releases 2024-2030 Action Plan on Sexually Transmitted and Blood-Borne Infections

Retrieved on: 
火曜日, 2月 27, 2024
Inhalation, Violence, Infection, Syphilis, CIHR, AIDS, Federation, Government, Action plan, Metis, Ectopic pregnancy, Viral hepatitis, First Nations, Science, Risk, Housing, Public, Research, Infertility, Cancer, Birth control

OTTAWA, ON, Feb. 27, 2024 /CNW/ - Sexually transmitted and blood-borne infections (STBBI) are largely preventable, treatable, and in many cases curable.

Key Points: 
  • OTTAWA, ON, Feb. 27, 2024 /CNW/ - Sexually transmitted and blood-borne infections (STBBI) are largely preventable, treatable, and in many cases curable.
  • However, rates of sexually transmitted infections in Canada have increased over the last decade—gonorrhea rates have doubled since 2012, and syphilis rates are five times what they were.
  • That is why today, the Honourable Mark Holland, Minister of Health, launched the Government of Canada's sexually transmitted and blood-borne infections (STBBI) action plan 2024-2030 and announced $2.45 million in funding to address STBBI in Canada.
  • The Action Plan will continue to work towards reducing STBBI related stigma, to prevent new and reoccurring infections and connect people to testing, prevention, treatment and care."

bioLytical Laboratories Inc. Donates Tests to Help Boost International Testing Access Ahead of International Testing Week

Retrieved on: 
水曜日, 11月 22, 2023
Partnership, HIV/AIDS, Infection, NGO, Health, MDSAP, Coalition, Hepatitis, STI, Public, HIV, Patient, Viral hepatitis, Vaccine

International Testing Week, scheduled for November 22- 28 this year, helps raise awareness of the importance of accessible testing for individual and public health.

Key Points: 
  • International Testing Week, scheduled for November 22- 28 this year, helps raise awareness of the importance of accessible testing for individual and public health.
  • Robert Mackie, CEO, bioLytical, emphasizes the significance of International Testing Week and states, "International Testing Week serves as a global reminder of the critical role rapid testing plays in safeguarding public health.
  • By donating these tests, bioLytical and Coalition PLUS aim to address the disparities in healthcare access and testing capabilities worldwide.
  • In 2022, bioLytical launched iStatis, its new lateral flow testing platform, to create additional access to testing worldwide.

Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023

Retrieved on: 
月曜日, 11月 13, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Hepatology, INSERM, Immunity, Interferon, Immune system, ALT, HDV, HBsAg, AASLD, Clinical trial, Viral hepatitis, EOT, Patient, Small RNA, Abstract, Week, Monoclonal antibody, Liver, Auckland City Hospital, CHB, University, Peginterferon-alfa, CHD, APHP, Hepatitis, Vir, RNA, Vaccine, Pharmaceutical industry, Communications satellite, Treatment, Medicine

To date, no participants receiving the combination therapy or VIR-3434 monotherapy have experienced ALT elevations relative to their baseline.

Key Points: 
  • To date, no participants receiving the combination therapy or VIR-3434 monotherapy have experienced ALT elevations relative to their baseline.
  • “Chronic hepatitis delta is the most aggressive form of viral hepatitis.
  • Vir will host an investor conference call to discuss the Phase 2 CHD & CHB AASLD data at 1:45 p.m. Pacific Time / 4:45 p.m. Eastern Time on November 13th.
  • A live webcast will be available on https://investors.vir.bio and will be archived on www.vir.bio for 30 days.

Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023

Retrieved on: 
金曜日, 11月 10, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Hepatology, INSERM, Interferon, AASLD, Viral hepatitis, Patient, EOT, Abstract, Monoclonal antibody, Liver, Auckland City Hospital, CHB, University, CHD, APHP, Hepatitis, Vaccine, Treatment, Medicine, Boston

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 and VIR-2218 could have for chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) patients at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Boston, MA, from November 10-14, 2023.

Key Points: 
  • Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 and VIR-2218 could have for chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) patients at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Boston, MA, from November 10-14, 2023.
  • These include one late-breaking poster presentation and one late-breaking oral presentation.
  • Title: VIR-2218 and VIR-3434 With or Without Pegylated Interferon Alfa-2A for the Treatment of Chronic HBV Infection: End of Treatment (EOT) Results After 24 Weeks of Therapy (March Study Part B) (Abstract #48500)
    Presenter: Edward Gane, M.D., Professor of Medicine at the University of Auckland, New Zealand, and Chief Hepatologist, Transplant Physician and Deputy Director of the New Zealand Liver Transplant Unit at Auckland City Hospital
    Title: The Monoclonal Antibody VIR-3434 And siRNA VIR-2218 for the Treatment of Chronic Hepatitis D Virus: Preliminary Results from the Phase 2 SOLSTICE Trial (Abstract #5004)
    Presenter: Tarik Asselah, M.D., Ph.D., Professor of Hepatology at the Hôpital Beaujon, APHP, Clichy, France, and at the University of Paris, and Head of Viral Hepatitis at INSERM UMR1149, France
    Vir will host an investor conference call to discuss the Phase 2 CHD & CHB AASLD data at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on November 13th.
  • A live webcast will be available on https://investors.vir.bio and will be archived on www.vir.bio for 30 days.

Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates

Retrieved on: 
水曜日, 11月 8, 2023
Research, IND, American Association for the Study of Liver Diseases, International, Infection, HSV, Therapy, Hepatology, Viral, Biotechnology, Liver, Viral hepatitis, Hepatitis D, Doctor of Philosophy, Gilead Sciences, Assembly, Partnership, Virology, Hepatitis B, Patient, HDV, HBV, AASLD, Pharmaceutical industry, Vaccine, Birth control, MD

Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyond

Key Points: 
  • Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyond
    SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today reported financial results for the third quarter ended September 30, 2023, and recent corporate updates.
  • We believe that the financial and scientific resources provided by the collaboration position us well to reach critical short- and long-term milestones and deliver value for patients and our shareholders.
  • Partnership includes Gilead opt-in rights on Assembly Bio’s current and future pipeline candidates, including two contributed Gilead herpesvirus programs.
  • Cash, cash equivalents and marketable securities were $46.2 million as of September 30, 2023, compared to $59.8 million as of June 30, 2023.